Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2011

Open Access 01-12-2011 | Original investigation

Dysglycemia induces abnormal circadian blood pressure variability

Authors: Sivarajan Kumarasamy, Kathirvel Gopalakrishnan, Dong Hyun Kim, Nader G Abraham, William D Johnson, Bina Joe, Alok K Gupta

Published in: Cardiovascular Diabetology | Issue 1/2011

Login to get access

Abstract

Background

Prediabetes (PreDM) in asymptomatic adults is associated with abnormal circadian blood pressure variability (abnormal CBPV).

Hypothesis

Systemic inflammation and glycemia influence circadian blood pressure variability.

Methods

Dahl salt-sensitive (S) rats (n = 19) after weaning were fed either an American (AD) or a standard (SD) diet. The AD (high-glycemic-index, high-fat) simulated customary human diet, provided daily overabundant calories which over time lead to body weight gain. The SD (low-glycemic-index, low-fat) mirrored desirable balanced human diet for maintaining body weight. Body weight and serum concentrations for fasting glucose (FG), adipokines (leptin and adiponectin), and proinflammatory cytokines [monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α)] were measured. Rats were surgically implanted with C40 transmitters and blood pressure (BP-both systolic; SBP and diastolic; DBP) and heart rate (HR) were recorded by telemetry every 5 minutes during both sleep (day) and active (night) periods. Pulse pressure (PP) was calculated (PP = SBP-DBP).

Results

[mean(SEM)]: The AD fed group displayed significant increase in body weight (after 90 days; p < 0.01). Fasting glucose, adipokine (leptin and adiponectin) concentrations significantly increased (at 90 and 172 days; all p < 0.05), along with a trend for increased concentrations of systemic pro-inflammatory cytokines (MCP-1 and TNF-α) on day 90. The AD fed group, with significantly higher FG, also exhibited significantly elevated circadian (24-hour) overall mean SBP, DBP, PP and HR (all p < 0.05).

Conclusion

These data validate our stated hypothesis that systemic inflammation and glycemia influence circadian blood pressure variability. This study, for the first time, demonstrates a cause and effect relationship between caloric excess, enhanced systemic inflammation, dysglycemia, loss of blood pressure control and abnormal CBPV. Our results provide the fundamental basis for examining the relationship between dysglycemia and perturbation of the underlying mechanisms (adipose tissue dysfunction induced local and systemic inflammation, insulin resistance and alteration of adipose tissue precursors for the renin-aldosterone-angiotensin system) which generate abnormal CBPV.
Appendix
Available only for authorised users
Literature
1.
go back to reference Björntorp P: The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord. 1996, 20 (4): 291-302. ReviewPubMed Björntorp P: The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord. 1996, 20 (4): 291-302. ReviewPubMed
2.
go back to reference Lev-Ran A: Human obesity: an evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev. 2001, 17 (5): 347-62. 10.1002/dmrr.230. ReviewCrossRefPubMed Lev-Ran A: Human obesity: an evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev. 2001, 17 (5): 347-62. 10.1002/dmrr.230. ReviewCrossRefPubMed
3.
go back to reference Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab. 2004, 89 (6): 2583-9. 10.1210/jc.2004-0535.CrossRefPubMed Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab. 2004, 89 (6): 2583-9. 10.1210/jc.2004-0535.CrossRefPubMed
4.
go back to reference Hamdy O, Porramatikul S, Al-Ozairi E: Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006, 2 (4): 367-73. ReviewCrossRefPubMed Hamdy O, Porramatikul S, Al-Ozairi E: Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006, 2 (4): 367-73. ReviewCrossRefPubMed
5.
go back to reference Blüher M: Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009, 117 (6): 241-50. 10.1055/s-0029-1192044. ReviewCrossRefPubMed Blüher M: Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009, 117 (6): 241-50. 10.1055/s-0029-1192044. ReviewCrossRefPubMed
6.
go back to reference Blüher M: The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol. 2010, 21 (1): 38-43. 10.1097/MOL.0b013e3283346ccc. ReviewCrossRefPubMed Blüher M: The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol. 2010, 21 (1): 38-43. 10.1097/MOL.0b013e3283346ccc. ReviewCrossRefPubMed
7.
go back to reference Gutierrez DA, Puglisi MJ, Hasty AH: Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep. 2009, 9 (1): 26-32. 10.1007/s11892-009-0006-9.PubMedCentralCrossRefPubMed Gutierrez DA, Puglisi MJ, Hasty AH: Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep. 2009, 9 (1): 26-32. 10.1007/s11892-009-0006-9.PubMedCentralCrossRefPubMed
8.
go back to reference Gupta AK, Cornelissen G, Greenway FL, Dhoopati V, Halberg F, Johnson WD: Abnormalities in circadian blood pressure variability and endothelial function: pragmatic markers for adverse cardiometabolic profiles in asymptomatic obese adults. Cardiovasc Diabetol. 2010, 9: 58-10.1186/1475-2840-9-58.PubMedCentralCrossRefPubMed Gupta AK, Cornelissen G, Greenway FL, Dhoopati V, Halberg F, Johnson WD: Abnormalities in circadian blood pressure variability and endothelial function: pragmatic markers for adverse cardiometabolic profiles in asymptomatic obese adults. Cardiovasc Diabetol. 2010, 9: 58-10.1186/1475-2840-9-58.PubMedCentralCrossRefPubMed
9.
go back to reference Gupta AK, Greenway FL, Cornelissen G, Pan W, Halberg F: Prediabetes is associated with abnormal circadian blood pressure variability. J Hum Hypertens. 2008, 22 (9): 627-33. 10.1038/jhh.2008.32.PubMedCentralCrossRefPubMed Gupta AK, Greenway FL, Cornelissen G, Pan W, Halberg F: Prediabetes is associated with abnormal circadian blood pressure variability. J Hum Hypertens. 2008, 22 (9): 627-33. 10.1038/jhh.2008.32.PubMedCentralCrossRefPubMed
10.
go back to reference Gupta AK, Menon A, Brasher M, Johnson WD: Prediabetes: Prevalence, Pathogenesis, and Recognition of Enhanced Risk. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Edited by: Bagchi D, Nair S. Chapter 5. Gupta AK, Menon A, Brasher M, Johnson WD: Prediabetes: Prevalence, Pathogenesis, and Recognition of Enhanced Risk. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Edited by: Bagchi D, Nair S. Chapter 5.
11.
go back to reference Gupta AK, Johnson WD: Prediabetes and prehypertension in disease free obese adults correlate with an exacerbated systemic proinflammatory milieu. J Inflamm. 2010, 7: 36-10.1186/1476-9255-7-36.CrossRef Gupta AK, Johnson WD: Prediabetes and prehypertension in disease free obese adults correlate with an exacerbated systemic proinflammatory milieu. J Inflamm. 2010, 7: 36-10.1186/1476-9255-7-36.CrossRef
12.
go back to reference Gupta AK, McGlone M, Greenway FL, Johnson WD: Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile. Hypertens Res. 2010, 33 (9): 905-10. 10.1038/hr.2010.91.CrossRefPubMed Gupta AK, McGlone M, Greenway FL, Johnson WD: Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile. Hypertens Res. 2010, 33 (9): 905-10. 10.1038/hr.2010.91.CrossRefPubMed
13.
go back to reference Gupta AK, Brashear MM, Johnson WD: Coexisting prehypertension and prediabetes in healthy adults: a pathway for accelerated cardiovascular events. Hypertens Res. 2011, 34 (4): 456-61. 10.1038/hr.2010.267.CrossRefPubMed Gupta AK, Brashear MM, Johnson WD: Coexisting prehypertension and prediabetes in healthy adults: a pathway for accelerated cardiovascular events. Hypertens Res. 2011, 34 (4): 456-61. 10.1038/hr.2010.267.CrossRefPubMed
14.
go back to reference Joe B, Garrett MR, Dene H, Rapp JP: Substitution mapping of a blood pressure quantitative trait locus to a 2.73 Mb region on rat chromosome 1. J Hypertens. 2003, 21: 2077-2084. 10.1097/00004872-200311000-00017.CrossRefPubMed Joe B, Garrett MR, Dene H, Rapp JP: Substitution mapping of a blood pressure quantitative trait locus to a 2.73 Mb region on rat chromosome 1. J Hypertens. 2003, 21: 2077-2084. 10.1097/00004872-200311000-00017.CrossRefPubMed
15.
go back to reference Shin JY, Lee HR, Lee DC: Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol. 2011, 10: 30-10.1186/1475-2840-10-30.PubMedCentralCrossRefPubMed Shin JY, Lee HR, Lee DC: Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol. 2011, 10: 30-10.1186/1475-2840-10-30.PubMedCentralCrossRefPubMed
16.
go back to reference Lakoski SG, Cushman M, Siscovick DS, Blumenthal RS, Palmas W, Burke G, Herrington DM: The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens. 2011, 25 (2): 73-9. 10.1038/jhh.2010.91.PubMedCentralCrossRefPubMed Lakoski SG, Cushman M, Siscovick DS, Blumenthal RS, Palmas W, Burke G, Herrington DM: The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens. 2011, 25 (2): 73-9. 10.1038/jhh.2010.91.PubMedCentralCrossRefPubMed
17.
go back to reference Bray GA: Obesity. Harrison's Principles of Internal Medicine. Edited by: Fauci AS, Braunwald E, Isselbacher KJ, et al. 1998, McGraw-Hill, New York, 454-62. 14 Bray GA: Obesity. Harrison's Principles of Internal Medicine. Edited by: Fauci AS, Braunwald E, Isselbacher KJ, et al. 1998, McGraw-Hill, New York, 454-62. 14
18.
go back to reference Wozniak SE, Gee LL, Wachtel MS, Frezza EE: Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009, 54 (9): 1847-56. 10.1007/s10620-008-0585-3.CrossRefPubMed Wozniak SE, Gee LL, Wachtel MS, Frezza EE: Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009, 54 (9): 1847-56. 10.1007/s10620-008-0585-3.CrossRefPubMed
19.
go back to reference Hajer GR, van Haeften TW, Visseren FL: Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008, 29 (24): 2959-71. 10.1093/eurheartj/ehn387.CrossRefPubMed Hajer GR, van Haeften TW, Visseren FL: Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008, 29 (24): 2959-71. 10.1093/eurheartj/ehn387.CrossRefPubMed
20.
go back to reference Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000, 35 (6): 1270-7.CrossRefPubMed Engeli S, Negrel R, Sharma AM: Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000, 35 (6): 1270-7.CrossRefPubMed
21.
go back to reference Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112: 1796-1808.PubMedCentralCrossRefPubMed Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112: 1796-1808.PubMedCentralCrossRefPubMed
22.
go back to reference Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Blüher M, Unger T, Wolf AM, Knippschild U, Hombach V, Marx N: T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 2008, 28: 1304-1310. 10.1161/ATVBAHA.108.165100.CrossRefPubMed Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Blüher M, Unger T, Wolf AM, Knippschild U, Hombach V, Marx N: T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 2008, 28: 1304-1310. 10.1161/ATVBAHA.108.165100.CrossRefPubMed
23.
go back to reference Duffaut C, Galitzky J, Lafontan M, Bouloumie' A: Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun. 2009, 384: 482-485. 10.1016/j.bbrc.2009.05.002.CrossRefPubMed Duffaut C, Galitzky J, Lafontan M, Bouloumie' A: Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun. 2009, 384: 482-485. 10.1016/j.bbrc.2009.05.002.CrossRefPubMed
24.
go back to reference Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R: CD8+ T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009, 15: 914-920. 10.1038/nm.1964.CrossRefPubMed Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R: CD8+ T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009, 15: 914-920. 10.1038/nm.1964.CrossRefPubMed
25.
go back to reference Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E, Chiesa C: Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol. 2006, 154: 691-697. 10.1530/eje.1.02138.CrossRefPubMed Pacifico L, Di Renzo L, Anania C, Osborn JF, Ippoliti F, Schiavo E, Chiesa C: Increased T-helper interferon-gamma-secreting cells in obese children. Eur J Endocrinol. 2006, 154: 691-697. 10.1530/eje.1.02138.CrossRefPubMed
26.
go back to reference Linton MF, Fazio S: Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord. 2003, 27 (Suppl 3): S35-S40.CrossRefPubMed Linton MF, Fazio S: Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord. 2003, 27 (Suppl 3): S35-S40.CrossRefPubMed
27.
go back to reference Antuna-Puente B, Feve B, Fellahi S, Bastard JP: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008, 34 (1): 2-11. 10.1016/j.diabet.2007.09.004.CrossRefPubMed Antuna-Puente B, Feve B, Fellahi S, Bastard JP: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008, 34 (1): 2-11. 10.1016/j.diabet.2007.09.004.CrossRefPubMed
28.
go back to reference Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444 (7121): 860-7. 10.1038/nature05485.CrossRefPubMed Hotamisligil GS: Inflammation and metabolic disorders. Nature. 2006, 444 (7121): 860-7. 10.1038/nature05485.CrossRefPubMed
29.
go back to reference Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci. 2008, 13: 453-461. 10.2741/2692.CrossRefPubMed Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci. 2008, 13: 453-461. 10.2741/2692.CrossRefPubMed
Metadata
Title
Dysglycemia induces abnormal circadian blood pressure variability
Authors
Sivarajan Kumarasamy
Kathirvel Gopalakrishnan
Dong Hyun Kim
Nader G Abraham
William D Johnson
Bina Joe
Alok K Gupta
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2011
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-10-104

Other articles of this Issue 1/2011

Cardiovascular Diabetology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine